Next Article in Journal
Multi-Organ Alcohol-Related Damage: Mechanisms and Treatment
Next Article in Special Issue
New Features about Tau Function and Dysfunction
Previous Article in Journal
Trying on tRNA for Size: RNase P and the T-box Riboswitch as Molecular Rulers
Previous Article in Special Issue
Nuclear Tau and Its Potential Role in Alzheimer’s Disease
Article Menu

Export Article

Erratum published on 12 August 2016, see Biomolecules 2016, 6(3), 35.

Open AccessArticle
Biomolecules 2016, 6(2), 19;

Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer’s Disease

Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK
Medical Research Council Cambridge Brain Bank Laboratory, Department of Psychiatry, University of Cambridge, Cambridge CB2 2QH, UK
TauRx Therapeutics Ltd. and School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Scotland AB25 2ZP, UK
Current address: Queen Elizabeth II Hospital, Howlands, Welwyn Garden City, Herts AL7 4HQ, UK.
Author to whom correspondence should be addressed.
Academic Editor: Jürg Bähler
Received: 13 December 2015 / Revised: 20 March 2016 / Accepted: 31 March 2016 / Published: 8 April 2016
(This article belongs to the Special Issue Tau Protein and Alzheimer’s disease)
Full-Text   |   PDF [2962 KB, uploaded 12 August 2016]   |  


Alzheimer’s disease is characterized by redistribution of the tau protein pool from soluble to aggregated states. Aggregation forms proteolytically stable core polymers restricted to the repeat domain, and this binding interaction has prion-like properties. We have compared the binding properties of tau and tubulin in vitro using a system in which we can measure binding affinities for proteins alternated between solid and aqueous phases. The study reveals that a phase-shifted repeat domain fragment from the Paired Helical Filament core contains all that is required for high affinity tau-tau binding. Unlike tau-tubulin binding, tau-tau binding shows concentration-dependent enhancement in both phase directions due to an avidity effect which permits one molecule to bind to many as the concentration in the opposite phase increases. Phosphorylation of tau inhibits tau-tau binding and tau-tubulin binding to equivalent extents. Tau-tau binding is favoured over tau-tubulin binding by factors in the range 19–41-fold, irrespective of phosphorylation status. A critical requirement for tau to become aggregation-competent is prior binding to a solid-phase substrate, which induces a conformational change in the repeat domain permitting high-affinity binding to occur even if tau is phosphorylated. The endogenous species enabling this nucleation event to occur in vivo remains to be identified. The findings of the study suggest that development of disease-modifying drugs for tauopathies should not target phosphorylation, but rather should target inhibitors of tau-tau binding or inhibitors of the binding interaction with as yet unidentified endogenous polyanionic substrates required to nucleate tau assembly. View Full-Text
Keywords: Alzheimer’s disease; tau protein; phosphorylation; protein aggregation Alzheimer’s disease; tau protein; phosphorylation; protein aggregation

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Lai, R.Y.K.; Harrington, C.R.; Wischik, C.M. Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer’s Disease. Biomolecules 2016, 6, 19.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Biomolecules EISSN 2218-273X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top